Zalicus: Expanding Drug Pipeline Helps Make It a Strong Buy
Investors may benefit from learning that in less than three months, Zalicus (ZLCS) has rolled out 3 new drug candidates. The share price has recently retraced from a high of $2.70 to $1.85 earlier this week.
Analysts have set a price target from $3 (Jason Napodano) to as high as $7 (Michael Murphy). The roll-out of these new drug candidates may infer this is a good time to buy Zalicus shares, who also recently reported a 152% royalty increase for its newly marketed drug Exalgo licensed to Covidien (COV).
It is also known that Zalicus is currently adding 20 million dollars of common shares facilitated by Wedbush to its 46 million dollar cash reserves reported at year-end 2010. The company also has a credit line of 20 million dollars.
On paper, it appears that Zalicus will be well-funded to aggressively move its clinical research forward. Therefore, given its cash position, currently depressed share price, and recently expanded clinical pipeline, I suggest Zalicus is a STRONG BUY.
Dedicated to pain and immuno-inflammatory drug development, Zalicus' new drugs are identified as Z160, Z212, and Z944. In the world of pain research, Zalicus is arguably among the leaders in what is called ion channel research. In simple terms, Zalicus is seeking to develop oral medications that target pain signaling in the human body. If successful, Zalicus's "Z" drugs would compete in a 20-30 billion dollar market, and particularly, against lucrative opioid drugs that are known to have serious side effects, including addiction.